Regarding US patent application for VAL001

Respiratorius announces decision from the Patent Trial and Appeal Board (PTAB) at the American Patent Office (USPTO) regarding the patent application for the formulation of VAL001. The PTBA has reversed all rejections of the examiner to both individual claims and the decision to reject the patent application, which means that the examiner must reopen the application. 

In addition to reversing the examiner's decision, the Patent Trial and Appeal Board does not point out any new rejections, which is considered as the examiner's ability to raise new rejections to the patent application is limited.

The patent application is Respiratorius' first concerning formulation and claims a new oral formulation of sodium valproate for the pre-treatment of cancer. The priority date for the patent application is April 21, 2016, and is valid for at least 20 years from the priority date, which if approved provides market exclusivity during this period. The corresponding application was approved in Japan in 2022 and in Canada in 2023.

This disclosure contains information that Respiratorius is obliged to make public pursuant to the EU Market Abuse Regulation (EU nr 596/2014). The information was submitted for publication, through the agency of the contact person, on 08-04-2024 14:44 CET.

Johan Drott
President Respiratorius AB
+46 709-22 41 40
johan.drott@respiratorius.com

Respiratorius AB (publ) is developing candidates for new effective drugs for the treatment of aggressive lymphoma. The company's business concept is to develop candidates for new drugs based on patent-pending substances, which in preclinical studies have shown superior results compared to what is currently considered standard treatment. For more information about Respiratorius, visit www.respiratorius.com.